pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KLRAKailera Therapeutics, Inc.

$KLRA13.70+5.63%
Waltham, MA, USupdated 10d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
ribupatide
Obesity

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injurycompletedn=5
  • phase2Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgiacompletedn=23
🐶 Hiring Signal
25 open roles at Kailera Therapeutics, Inc. →

Where Kailera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaMetabolic 24Oncology 1
departmentPeople & Talent 5Regulatory 4Manufacturing / CMC 4Clinical 4Quality 3Medical Affairs 2

News

  • The 6 biggest crossover rounds in biopharma history
    A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.
    biospace · 1mo ago
  • Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
    Amid the Chinese biotech licensing boom, Hengrui Pharmaceuticals stands out from the crowd. The Jiangsu-based biopharma landed one of the largest licensing deals ever by a Chinese company courtesy…
    fiercebiotech · 1mo ago
  • Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
    Jennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…
    biospace · 3mo ago
  • Biotech startup funding gap widens despite rebound in VC investment
    Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
    biopharma_dive · 4mo ago
  • At BIO, tension over China biotech deal regulation looms
    Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
    biopharma_dive · 4mo ago
  • Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
    biopharma_dive · 6mo ago
identifiers
ticker
$KLRA
SEC CIK
0002096997
country
US
source
sec_tickers
top tags
Obesity1Type 2 Diabetes1
mentioned in
6news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?